Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants (scientific article published on December 2011)

Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection

Q33813762

The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity

Q33991546

Chikungunya outbreaks--the globalization of vectorborne diseases

Q34002554

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response

Q34110965

Directed egress of animal viruses promotes cell-to-cell spread

Q34327423

Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures

Q34485363

Prophylaxis and therapy for Chikungunya virus infection

Q34990306

Heparan sulfate binding can contribute to the neurovirulence of neuroadapted and nonneuroadapted Sindbis viruses

Q35785100

Chikungunya virus, southeastern France

Q35876743

pH-induced alterations in the fusogenic spike protein of Semliki Forest virus

Q36214003

pH-dependent fusion between the Semliki Forest virus membrane and liposomes

Q36392548

Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants

Q36797624

Chikungunya fever: an epidemiological review of a re-emerging infectious disease

Q37575480

Chikungunya: a bending reality

Q37595871

Virus cell-to-cell transmission.

Q37726587

Structural rearrangement of infecting Sindbis virions at the cell surface: mapping of newly accessible epitopes

Q38316699

Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site

Q39132098

Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor.

Q39580237

A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years

Q40372969

Chikungunya virus infection of cell monolayers by cell-to-cell and extracellular transmission

Q40712746

Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread

Q40761451

Bovine herpesvirus 1 requires glycoprotein H for infectivity and direct spreading and glycoproteins gH(W450) and gB for glycoprotein D-independent cell-to-cell spread

Q40975080

Antigenic and genetic characterization of Sindbis virus monoclonal antibody escape mutants which define a pathogenesis domain on glycoprotein E2.

Q41741530

Chikungunya virus aches and pains: an emerging challenge

Q41940293

Chikungunya: first steps toward specific treatment and prophylaxis

Q42989057

Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies

Q43041465

Infectious diseases. Chikungunya: no longer a third world disease

Q43048076

Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein

Q43842776

Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island

Q44851009

Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice

Q45740291

Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection

Q45789498

Location of a major antigenic site involved in Ross River virus neutralization

Q45847743

A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease

Q21559504

Avoiding the void: cell-to-cell spread of human viruses

Q22251022

Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages

Q24288996

Viral mutation rates

Q24611162

Mutation rates among RNA viruses

Q24643023

Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion

Q27485485

Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells

Q27486033

Arbovirus evolution in vivo is constrained by host alternation

Q27486082

Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection

Q27486388

A conformational change in Sindbis virus glycoproteins E1 and E2 is detected at the plasma membrane as a consequence of early virus-cell interaction

Q27486596

Antibody-selected variation and reversion in Sindbis virus neutralization epitopes

Q27486798

Structural proteins of Chikungunya virus

Q27486904

Accurate Strand-Specific Quantification of Viral RNA

Q27490032

Impact of Chikungunya Virus Infection on Health Status and Quality of Life: A Retrospective Cohort Study

Q27490293

The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH

Q27631190

Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus

Q27643010

Structural changes of envelope proteins during alphavirus fusion

Q27666145

Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography

Q27666147

The alphaviruses: gene expression, replication, and evolution

Q27860954

Genetic Diversity and Slow Rates of Evolution in New World Alphaviruses

Q28210552

Infection with chikungunya virus in Italy: an outbreak in a temperate region

Q29346487

Rapid evolution of RNA genomes

Q29616272

An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features

Q29620004

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

chikungunya

Q243257

Chikungunya virus

Q15794049

chikungunya virus transmission

Q56452831

P5008

on focus list of Wikimedia project

ScienceSource

Q55439927

P304

page(s)

e1002390

P577

publication date

2011-12-01

P1433

published in

PLOS Pathogens

Q283209

P1476

title

Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants

P478

volume

Reverse relations

cites work (P2860)

Q90263559	A comparison of Chikungunya virus infection, progression, and cytokine profiles in human PMA-differentiated U937 and murine RAW264.7 monocyte derived macrophages
Q28533408	A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease
Q38329445	A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization
Q36914762	An essential role of antibodies in the control of Chikungunya virus infection
Q40232847	Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis
Q35574887	Analysis of the genetic diversity of influenza A viruses using next-generation DNA sequencing
Q89794663	Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection
Q66680697	Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus
Q40083142	Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission
Q48095971	Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community
Q91593119	Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated In Vivo and Have Compromised Transmissibility
Q38118022	Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy
Q26700081	Chikungunya vaccines in development
Q38527379	Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
Q24701786	Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes
Q42923192	Chronic inflammatory arthritis with persisting bony erosions in patients following chikungunya infection
Q40062417	Clinical, Serological and Virological analysis of 572 chikungunya patients during the years 2010-2013 from India
Q24276414	Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine
Q27335008	Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus
Q24701766	Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy
Q54247380	Human-Like Neutralizing Antibodies Protect Mice from Aerosol Exposure with Western Equine Encephalitis Virus.
Q35078457	Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island
Q36257616	Identification of Functional Determinants in the Chikungunya Virus E2 Protein
Q39013750	Immune-Mediated Protection and Pathogenesis of Chikungunya Virus
Q36225228	Intercellular Extensions Are Induced by the Alphavirus Structural Proteins and Mediate Virus Transmission
Q35850197	Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus
Q27013018	Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins
Q36397446	Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development
Q54111086	Miltefosine inhibits Chikungunya virus replication in human primary dermal fibroblasts.
Q40077669	Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus
Q91900087	Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Q38078178	Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
Q39222637	Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release
Q24701792	Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection
Q37214518	Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence
Q24289014	Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections
Q28068946	Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies
Q35238179	Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge
Q38716498	Spatial and Temporal Analysis of Alphavirus Replication and Assembly in Mammalian and Mosquito Cells
Q40922578	Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission
Q35711583	Suramin Inhibits Chikungunya Virus Entry and Transmission
Q54268571	The Alphavirus Exit Pathway: What We Know and What We Wish We Knew.
Q42983207	The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry
Q91605138	Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure
Q39012242	Use of human monoclonal antibodies to treat Chikungunya virus infection
Q28504479	Viperin restricts chikungunya virus replication and pathology